News

Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

North American Morning Briefing: Stock Futures Rise as Investors Weigh Trade Talks, Earnings

-U.S. futures for the S&P 500 and Dow Jones Industrial Average rose 0.1% and Nasdaq futures gained 0.3%. Earnings will come today from Boeing, Spotify, United Health, Procter & Gamble, Visa and PayPal ...
SWI swissinfo.ch17h

Stocks Hold at Record, Dollar Jumps on Trade Hopes: Markets Wrap

Wall Street traders left stocks at all-time highs while the dollar climbed the most since May, with a tariff deal between ...

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Sarepta's FDA woes raise questions for future of gene therapy treatments

Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy ...
Seeking Alpha on MSN12h

Sarepta upgraded to Neutral at J.P. Morgan, Outperform at Oppenheimer

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.
SWI swissinfo.ch7h

S&P 500 Snaps Six-Day Winning Run as Bonds Climb: Markets Wrap

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...